Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
179 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H1 2017 Summary Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 33 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2017, outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 2, 5, 8, 9, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Immunology, Central Nervous System, Gastrointestinal, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Respiratory and Undisclosed which include indications Solid Tumor, Melanoma, Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ovarian Cancer, Pancreatic Cancer, Tenosynovial Giant Cell Tumor, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Breast Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, Pigmented Villonodular Synovitis, Bladder Cancer, Colorectal Cancer, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Inflammation, Metastatic Colorectal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bone Metastasis, Colon Cancer, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Follicular Thyroid Cancer, Lung Adenocarcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Thyroid Cancer, Acral Lentiginous Melanoma, Acute Ischemic Stroke, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Autoimmune Disorders, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Depression, Dysthymia, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Endometrial Cancer, Ewing Sarcoma, Fibrosarcoma, Gallbladder Cancer, Germ Cell Tumors, Gliosarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Lung Cancer, Malignant Ascites, Malignant Mesothelioma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Biliary Tract Cancer, Metastatic Liver Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, Non-Small Cell Lung Carcinoma, Osteolysis, Osteosarcoma, Pain, Pancreatic Ductal Adenocarcinoma, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Pheochromocytoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Refractory Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Renal Failure, Rhabdomyosarcoma, Rheumatoid Arthritis, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Unspecified, Urticaria Pigmentosa (Mastocytosis, Mastocytoma) and Uveal Melanoma. Furthermore, this report also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Overview Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development AB Science SA Amgen Inc Array BioPharma Inc BCI Pharma Bristol-Myers Squibb Company Cielo Therapeutics Inc CrystalGenomics Inc CTI BioPharma Corp Deciphera Pharmaceuticals LLC Eli Lilly and Company Elsalys Biotech SAS F. Hoffmann-La Roche Ltd Hutchison China MediTech Ltd Ignyta Inc Johnson & Johnson Nerviano Medical Sciences Srl Novartis AG Pfizer Inc Plexxikon Inc Redx Pharma Plc SignalChem Lifesciences Corp Syndax Pharmaceuticals Inc Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Drug Profiles AMG-820 - Drug Profile Product Description Mechanism Of Action R&D Progress ARRY-382 - Drug Profile Product Description Mechanism Of Action R&D Progress BLZ-945 - Drug Profile Product Description Mechanism Of Action R&D Progress cabiralizumab - Drug Profile Product Description Mechanism Of Action R&D Progress DCC-3014 - Drug Profile Product Description Mechanism Of Action R&D Progress ELB-041 - Drug Profile Product Description Mechanism Of Action R&D Progress emactuzumab - Drug Profile Product Description Mechanism Of Action R&D Progress GW-2580 - Drug Profile Product Description Mechanism Of Action R&D Progress HMPL-012 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-28312141 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-40346527 - Drug Profile Product Description Mechanism Of Action R&D Progress LY-3022855 - Drug Profile Product Description Mechanism Of Action R&D Progress masitinib - Drug Profile Product Description Mechanism Of Action R&D Progress NMS-088 - Drug Profile Product Description Mechanism Of Action R&D Progress NMSP-088 - Drug Profile Product Description Mechanism Of Action R&D Progress pacritinib - Drug Profile Product Description Mechanism Of Action R&D Progress pazopanib hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress pazopanib hydrochloride + pembrolizumab - Drug Profile Product Description Mechanism Of Action R&D Progress PD-0360324 - Drug Profile Product Description Mechanism Of Action R&D Progress pexidartinib - Drug Profile Product Description Mechanism Of Action R&D Progress PLX-73086 - Drug Profile Product Description Mechanism Of Action R&D Progress PLX-7486 - Drug Profile Product Description Mechanism Of Action R&D Progress RXDX-105 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibitor CSF1R for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize CSF-1 Receptor for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize CSF-1R for Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit FMS for Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Target CSF-1R - Drug Profile Product Description Mechanism Of Action R&D Progress SNDX-6352 - Drug Profile Product Description Mechanism Of Action R&D Progress sunitinib malate - Drug Profile Product Description Mechanism Of Action R&D Progress Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Dormant Products Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Discontinued Products Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Product Development Milestones Featured News & Press Releases Jun 04, 2017: Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting May 31, 2017: Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT (Sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery May 18, 2017: Chi-Med Presents Clinical Data on Sulfatinib at ASCO 2017 Annual Meeting May 18, 2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib) May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting May 17, 2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards Apr 20, 2017: Five Prime to Present Clinical Data on cabiralizumab at 2017 ASCO Annual Meeting Apr 10, 2017: Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis Apr 07, 2017: Chi-Med Presented Pre-clinical Data for Sulfatinib at the American Association for Cancer Research Annual Meeting 2017 Apr 03, 2017: Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) Mar 20, 2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis Mar 10, 2017: Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..5), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by AB Science SA, H1 2017 Pipeline by Amgen Inc, H1 2017 Pipeline by Array BioPharma Inc, H1 2017 Pipeline by BCI Pharma, H1 2017 Pipeline by Bristol-Myers Squibb Company, H1 2017 Pipeline by Cielo Therapeutics Inc, H1 2017 Pipeline by CrystalGenomics Inc, H1 2017 Pipeline by CTI BioPharma Corp, H1 2017 Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 Pipeline by Eli Lilly and Company, H1 2017 Pipeline by Elsalys Biotech SAS, H1 2017 Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Pipeline by Hutchison China MediTech Ltd, H1 2017 Pipeline by Ignyta Inc, H1 2017 Pipeline by Johnson & Johnson, H1 2017 Pipeline by Nerviano Medical Sciences Srl, H1 2017 Pipeline by Novartis AG, H1 2017 Pipeline by Pfizer Inc, H1 2017 Pipeline by Plexxikon Inc, H1 2017 Pipeline by Redx Pharma Plc, H1 2017 Pipeline by SignalChem Lifesciences Corp, H1 2017 Pipeline by Syndax Pharmaceuticals Inc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Dormant Products, H1 2017 (Contd..2), H1 2017 Dormant Products, H1 2017 (Contd..3), H1 2017 Dormant Products, H1 2017 (Contd..4), H1 2017 Discontinued Products, H1 2017 Discontinued Products, H1 2017 (Contd..1), H1 2017 Discontinued Products, H1 2017 (Contd..2), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
